Sclerotherapy in the management of low flow Venous malformations

The field of vascular anomalies is rapidly growing and has significantly evolved during the recent decades,¿Vascular malformation¿ is a generalized term used to describe a group of lesions, present at birth, formed by an anomaly of angiovascular or lymphovascular structures.Sclerotherapy is considered to be a better treatment modality for VMs and denatures the protein of the malformed vessel walls and damages the endothelium to form the thrombus.Polidocanol also known as lauromacrogol or aethoxysclerol (chemical name: lauryl alcohol polyoxyethylene),It produces an acute lesion of the vascular endothelium, which triggers the ¿cascade¿ of coagulation. It crosses the placental barrier so is not advised for pregnant women. The incidence of allergies is low, the injection is pain less, and skin necroses are rare.The aim of our research was to establish the efficacy of Polidocanol in the management of low flow venous malformations in maxillofacial region